(37 days)
Not Found
No
The description details a standard immunoassay technology (CMIA) and does not mention any AI or ML components in the device's operation or data analysis.
No
This device is an in-vitro diagnostic (IVD) assay designed to quantitatively determine CK-MB levels to assist in the diagnosis of myocardial infarction. It does not provide treatment or therapy.
Yes
The intended use explicitly states that "CK-MB values are used to assist in the diagnosis of myocardial infarction (MI)," which is a diagnostic purpose.
No
The device description clearly outlines a chemical assay involving reagents, microparticles, and a chemiluminescent reaction measured by an optical system, indicating a hardware-based laboratory instrument and associated consumables, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "quantitative determination of CK-MB in human serum and plasma." This involves testing biological samples in vitro (outside the body).
- Device Description: The description details a laboratory assay (Chemiluminescent Microparticle Immunoassay - CMIA) that analyzes components of blood samples (serum and plasma).
- Purpose: The purpose is to "assist in the diagnosis of myocardial infarction (MI)" by measuring a specific biomarker (CK-MB) in these samples. This is a diagnostic purpose performed in vitro.
All these points align with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
ARCHITECT STAT CK-MB is a Chemiluminescent Micropaticle Immunoassay (CMIA) for the quantitative determination of CK-MB in human serum and plasma on the ARCHITECT i System with STAT capability. CK-MB values are used to diagnosis of myocardial infarction (MI).
Product codes (comma separated list FDA assigned to the subject device)
MMI, JHX, JIS
Device Description
The ARCHITECT STAT CK-MB assay is a two-step assay to determine the presence of the MB isoenzyme of creatine kinase (CK-MB) in human serum and plasma using CMA technology with flexible assay protocols, referred to as Chemiflex®.
In the first step, sample and anti-CK-MB coated paramagnetic microparticles are combined. After incubation and washing, anti-CK-MB acridinium conjugate is added in the second step. Following another incubation and wash, pre-trigger and trigger solutions are added to the reaction mixture. The resulting chemiluminescent reaction is measured as relative light units (RLUs). A direct relationship exists between the amount of CK-MB in the sample and the RLUs detected by the ARCHITECT i* optical system.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The ARCHITECT® STAT CK-MB assay is substantially equivalent to the Abbott AxSYM® CK-MB assay in terms of precison, linearity, interferences, and stability as demonstrated in non-clinical performance data in this 510(k) submission.
The ARCHITECT STAT CK-MB assay demonstrated substantially equivalent to the AxSYM® CK-MB assay. The sample stability study evaluated ARCHITECT STAT CK-MB assay using Lithium Heparin and Serum Separator collection tubes. There was no systematic gain or loss of the detectability of CK-MB in serum or plasma samples under any of the storage conditions evaluated in this study. A method comparison using the NCCLS Bias Estimation Standard (EP-9A) was also conducted with the ARCHITECT STAT CK-MB and AxSYM® CK-MB assays and as a result, the two systems demonstrated substantial equivalence as indicated by clinical data in this 510(k) submission.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1215 Creatine phosphokinase/creatine kinase or isoenzymes test system.
(a)
Identification. A creatine phosphokinase/creatine kinase or isoenzymes test system is a device intended to measure the activity of the enzyme creatine phosphokinase or its isoenzymes (a group of enzymes with similar biological activity) in plasma and serum. Measurements of creatine phosphokinase and its isoenzymes are used in the diagnosis and treatment of myocardial infarction and muscle diseases such as progressive, Duchenne-type muscular dystrophy.(b)
Classification. Class II.
0
6.3 Summary of Safety and Effectiveness
This summary of the 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990.
JUL 2 1 2004
Applicant Name:
Josefina Infantas, MSM Sr. Regulatory Affairs Specialist Fisher Diagnostics 8365 Valley Pike P.O. Box 307 Middletown, VA 22645 Phone: 540-869-8158 Fax: 540-869-8129
Establishment Registration Number: 1181121
Identification of Device:
Device Name: ARCHITECT® STAT CK-MB immunoassay Proprietary/Trade Name: ARCHITECT® STAT CK-MB immunoassay Common Name: CK-MB test system Device Classification: Class II Governing Regulation: 21 CFR 862.1215 FDA Panel: Clinical Chemistry Product Code: MMI THIX
Identification of Predicate Device:
Abbott AxSYM® CK-MB Assay (K935924)
Intended Use of the Device:
ARCHITECT STAT CK-MB is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of CK-MB in human serum and plasma on the ARCHITECT i System with STAT capability. CK-MB values are used to assist in the diagnosis of myocardial infarction (MI).
Description of the Device:
The ARCHITECT STAT CK-MB assay is a two-step assay to determine the presence of the MB isoenzyme of creatine kinase (CK-MB) in human serum and plasma using CMA technology with flexible assay protocols, referred to as Chemiflex®
In the first step, sample and anti-CK-MB coated paramagnetic microparticles are combined. After incubation and washing, anti-CK-MB acridinium conjugate is added in the second step. Following another incubation and wash, pre-trigger and trigger solutions are added to the reaction mixture. The resulting chemiluminescent reaction is measured as relative light units (RLUs). A direct relationship exists between the amount of CK-MB in the sample and the RLUs detected by the ARCHITECT i* optical system.
Comparison of Technological Characteristics:
The ARCHITECT® STAT CK-MB and the AxSYM® CK-MB assays use a microparticle immunoassay method for the quantitative determination of creatine kinase (CK-MB) in human serum or plasma. Values obtained are used to assist in the diagnosis of
Confidential
1
myocardial infarction. Anti-microbial agent is used as a preservative for all reagent components (microparticles and conjugate) of the AxSYM® CK-MB assay as well as the ARCHITECT STAT CK-MB. Both assays have microparticles coated with mouse monoclonal anti-CK-MB in TRIS buffer.
CK-MB is an 84,000 molecular weight enzyme that represents a significant fraction of the creatine kinase present in myocardial tissue. CK-MB is also present in a variety of other tissues, although at much lower levels. The appearance of CK-MB in serum, in the absence of major muscle trauma, may be indicative of cardiac damage and thus, myocardial infarction (MI). MI is defined as myocardial cell death due to prolonged ischemia. The magnitude and temporal course of CK-MB elevation and decline may clarify the timing of the myocardial insult, allow an estimate of infarct size, and contribute to the non-invasive assessment of reperfusion.
Summary of Non-clinical Performance:
The ARCHITECT® STAT CK-MB assay is substantially equivalent to the Abbott AxSYM® CK-MB assay in terms of precison, linearity, interferences, and stability as demonstrated in non-clinical performance data in this 510(k) submission.
Summary of Clinical Performance:
The ARCHITECT STAT CK-MB assay demonstrated substantially equivalent to the AxSYM® CK-MB assay. The sample stability study evaluated ARCHITECT STAT CK-MB assay using Lithium Heparin and Serum Separator collection tubes. There was no systematic gain or loss of the detectability of CK-MB in serum or plasma samples under any of the storage conditions evaluated in this study. A method comparison using the NCCLS Bias Estimation Standard (EP-9A) was also conducted with the ARCHITECT STAT CK-MB and AxSYM® CK-MB assays and as a result, the two systems demonstrated substantial equivalence as indicated by clinical data in this 510(k) submission.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with its wings spread, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" are arranged in a circle around the eagle. The logo is black and white.
Public Health Service
JUL 2 1 2004
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Josefina Infantas, MSM Sr. Regulatory Affairs Specialist Fisher Diagnostics 8365 Valley Pike PO Box 307 Middletown, VA 22645
K041596 Re:
Trade/Device Name: ARCHITECT® STAT CK-MB Immunoassay Regulation Number: 21 CFR 862.1215 Regulation Name: Creatine phosphokinase/creatine kinase or isoenzymes test system Regulatory Class: Class II Product Code: JHX, JIS Dated: June 10, 2004 Received: June 14, 2004
Dear Ms. Infantas:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
3
Page 2
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Jean M. Cooper MS, DVM.
Yean M. Cooper, MS, D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
ARCHITECT® STAT CK-MB Assay June 9, 2004
6.1 Indications for Use
ARCHITECT STAT CK-MB is a Chemiluminescent Micropaticle Immunoassay (CMIA)
Chilian Children Chemical of OK MD in human serum and plasma on the ARCHITECT STAT CK-MB is a Chemilluminesoon masepara and plasma on the may on the first for the quantitative determination of CR-MB in haman occare and provinsity of the same of the Market in the
ARCHITECT i System with STAT capability. CK-MB values are used to diagnosis of myocardial infarction (MI).
510 (k) Number (if known): K041596
Device Name: ARCHITECT® STAT CK-MB Immunoassay
Use Prescription × -AND/OR (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Carol Benson
Division Sign Off
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K041596
Confidential
Page 74 of 113